Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)

NCT06311214 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06311214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06311214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Antibody-Drug Conjugate Therapy Through Molecular Analysis for Therapy Choice (ADC MATCH)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
March 18, 2025
Completion date
March 31, 2028
Enrollment
500 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm